What are the limitations of the who 2021 cns class?

While the who 2021 cns class is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the who 2021 cns class to ensure safe bedside use and optimal diagnostic accuracy.

How does the who 2021 cns class compare to other Oncology scores?

The who 2021 cns class is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the who 2021 cns class free to use?

Yes. OpiCalc provides the who 2021 cns class completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

WHO 2021 CNS Class.

Head, Neck & CNS

Integrated CNS tumor classifier using IDH, 1p/19q, EGFR, chromosome 7/10, CDKN2A/B, and necrosis/MVP patterns.

IDH mutation

1p/19q codeletion

CDKN2A/B homozygous deletion

TERT promoter mutation

EGFR amplification

Combined chromosome +7 / -10 signature

Necrosis or microvascular proliferation

Calculated Interpretation

Diffuse Astrocytoma / Requires Integration

WHO 2021 CNS entities are defined by integrated histologic and molecular criteria.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Integrated CNS tumor classifier using IDH, 1p/19q, EGFR, chromosome 7/10, CDKN2A/B, and necrosis/MVP patterns.

CLINICAL INSIGHT

How it Works

Clinical Inputs

IDH mutation

1p/19q codeletion

CDKN2A/B homozygous deletion

TERT promoter mutation

EGFR amplification

Combined chromosome +7 / -10 signature

Necrosis or microvascular proliferation

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Integrated CNS tumor classifier using IDH, 1p/19q, EGFR, chromosome 7/10, CDKN2A/B, and necrosis/MVP patterns.

OpiCalc Medical Oncology ModuleHead, Neck & CNS2026

CLINICAL INSIGHT

Background

Context

WHO 2021 CNS Class. is included in the oncology module as a structured decision-support tool for head, neck & cns workflows.

No clinical reference data available.

WHO 2021 CNS Class.

Head, Neck & CNS

Integrated CNS tumor classifier using IDH, 1p/19q, EGFR, chromosome 7/10, CDKN2A/B, and necrosis/MVP patterns.

IDH mutation

1p/19q codeletion

CDKN2A/B homozygous deletion

TERT promoter mutation

EGFR amplification

Combined chromosome +7 / -10 signature

Necrosis or microvascular proliferation

Calculated Interpretation

Diffuse Astrocytoma / Requires Integration

WHO 2021 CNS entities are defined by integrated histologic and molecular criteria.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Integrated CNS tumor classifier using IDH, 1p/19q, EGFR, chromosome 7/10, CDKN2A/B, and necrosis/MVP patterns.

CLINICAL INSIGHT

How it Works

Clinical Inputs

IDH mutation

1p/19q codeletion

CDKN2A/B homozygous deletion

TERT promoter mutation

EGFR amplification

Combined chromosome +7 / -10 signature

Necrosis or microvascular proliferation

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Integrated CNS tumor classifier using IDH, 1p/19q, EGFR, chromosome 7/10, CDKN2A/B, and necrosis/MVP patterns.

OpiCalc Medical Oncology ModuleHead, Neck & CNS2026

CLINICAL INSIGHT

Background

Context

WHO 2021 CNS Class. is included in the oncology module as a structured decision-support tool for head, neck & cns workflows.

No clinical reference data available.